Phase 2 Eczema Trial, Recruiting (NCT07211542)

Phase 2 Eczema Trial, Recruiting NCT07211542 Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd Condition: Eczema

Printed from Voxsanity (voxsanity.com.au) — NCT07211542 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Eczema

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are willing to sign a consent form, can communicate with the research team, and agree to follow the study rules throughout the trial.
You are between 18 and 75 years old (inclusive) at the time of signing the consent form, and can be male or female.
You have been identified as having atopic dermatitis (a type of chronic skin condition that causes itchy, inflamed skin) at the screening stage.

Who may not be able to join:

You have a known allergy or sensitivity to the study drug or any of its ingredients.
You have another active skin condition or skin problem caused by something else that could make it harder to assess your atopic dermatitis.
You currently have cancer, or have had cancer at any point in the past.
You have a serious ongoing illness or other health condition that the trial doctor feels makes it unsafe or unsuitable for you to take part (confirm with trial site).
You are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-0518-82342973

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07211542

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

Phase: Phase 2

Status: Recruiting

Condition: Eczema

Trial contact: +86-0518-82342973

More information: https://clinicaltrials.gov/study/NCT07211542

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are willing to sign a consent form, can communicate with the research team, and agree to follow the study rules throughout the trial.
You are between 18 and 75 years old (inclusive) at the time of signing the consent form, and can be male or female.
You have been identified as having atopic dermatitis (a type of chronic skin condition that causes itchy, inflamed skin) at the screening stage.

Who may not be able to join:

You have a known allergy or sensitivity to the study drug or any of its ingredients.
You have another active skin condition or skin problem caused by something else that could make it harder to assess your atopic dermatitis.
You currently have cancer, or have had cancer at any point in the past.
You have a serious ongoing illness or other health condition that the trial doctor feels makes it unsafe or unsuitable for you to take part (confirm with trial site).
You are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd

Registry

ClinicalTrials.gov

Start date

7 November 2025

Est. completion

1 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The proportion of subjects whose Eczema Area and Severity Index (EASI) score decreased ≥ 75% compared to the baseline.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov